14 pharmaceutical acquisitions in 2020

14 pharmaceutical acquisitions this year, as reported by Becker’s Hospital Review: 

Editor’s note: This is not an exhaustive list. Acquisitions are listed in chronological order. 

1. Eli Lilly to acquire small California biotech for $1.1 billion
   Eli Lilly acquired Dermira, a small Menlo Park, Calif.-based drugmaker that specializes in chronic skin conditions, for $1.1 billion.
2. Gilead acquires cancer biotech for $4.9B
   Gilead acquired Menlo Park, Calif.-based cancer biotech Forty Seven for $4.9 billion.
3. CVS to acquire St. Louis grocery chain’s pharmacy business
   CVS Pharmacy acquired all 110 of St. Louis-based grocery store chain Schnucks’ retail and specialty pharmacies.
4. J&J to acquire Momenta Pharma for $6.5B
   Johnson & Johnson bought Cambridge, Mass.-based Momenta Pharmaceuticals for $6.5 billion, a move to strengthen the drugmaker’s portfolio of autoimmune disease treatments.
5. Acadia Pharmaceuticals acquires Texas drugmaker for $52.5M
   Acadia Pharmaceuticals acquired Fort Worth, Texas-based biotech CerSci Therapeutics for $52.5 million, a move that broadened the San Diego-based drugmaker’s pain medication portfolio.
6. Nestle acquires Aimmune Therapeutics for $2.6B
   Nestle paid $2.6 billion to acquire Brisbane, Calif.-based Aimmune Therapeutics, a move that broadens the Swiss food company’s health science portfolio.
7. Bayer to acquire vitamin subscription company for $225M
   Bayer will purchase Care/of, an online vitamin and supplement provider, in efforts to expand its nutrition and wellness portfolio.
8. Gilead expands oncology portfolio, acquires Immunomedics for $21B
   Gilead purchased Immunomedics, a Morris Plains, N.J.-based cancer drugmaker, for $21 billion.
9. UnitedHealth acquires competitor to Amazon’s PillPack
   UnitedHealth Group acquired DivvyDose, a startup that delivers medications in presorted packages and competes with Amazon’s PillPack.
10. Bristol Myers Squibb acquires MyoKardia for $13B
    Bristol Myers Squibb inked a $13.1 billion deal to buy Brisbane, Calif.-based drugmaker MyoKardia, aiming to diversify its drug portfolio beyond oncology medicines. 
11. Rite Aid to acquire Seattle-based pharmacy chain for $95M
    Rite Aid acquired Seattle-based pharmacy chain Bartell Drugs for $95 million.
12. Bayer acquires gene therapy company for $4B
    Bayer bought gene therapy company Asklepios BioPharmaceutical, commonly known as AskBio, in a deal totaling $4 billion.
13. Merck to acquire COVID-19 drug developer for $425M
    Merck announced it will buy Rockville, Md.-based drugmaker OncoImmune for an upfront cash payment of $425 million to obtain rights to the drug it’s developing for patients hospitalized with severe and critical COVID-19.
14. Gilead to pay $1.4B for hepatitis drugmaker
    Gilead said it plans to buy German drugmaker MYR GmbH for $1.4 billion to gain access to its drug Hepcludex, which treats adults with chronic hepatitis delta virus infection.

More articles on pharmacy:
Pfizer COVID-19 vaccine doses get too cold, must be returned in 2 states
CVS begins $3M initiative to increase access to flu shots in underserved areas
Gilead to pay $1.4B for hepatitis drugmaker

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.